MANILA, Philippines - 22 May 2025 – Ayala Healthcare Holdings, Inc. (AC Health) and Becton Dickinson Holdings Pte Ltd (BD), a leading global medical technology company, have announced a strategic collaboration through a Memorandum of Understanding (MoU) focused on driving innovation, enhancing healthcare delivery, and improving patient outcomes across the Philippines and Southeast Asia.
.jpg)
This joint effort combines AC Health’s integrated healthcare ecosystem with BD’s global expertise in medical technology, focusing on key initiatives supporting clinical optimization, digital integration, supply chain efficiency, public health programs, research and development, and professional education.
The collaboration will concentrate on several key areas. To optimize patient care and operational effectiveness, AC Health and BD will work together on clinical consulting and workflow optimization, aiming to enhance efficiency and quality of care. In healthcare innovation and digital transformation, the collaboration will introduce advanced technologies and digital solutions to AC Health’s network.
Furthermore, the collaboration will address supply chain and operational efficiency. Recognizing the importance of public health, both organizations will engage in public health and disease management initiatives, including efforts for early disease detection, prevention and treatment, with a specific focus on collaborative programs for infectious disease management and vaccination.
The collaboration also encompasses future research and development, where AC Health and BD will partner on exploring research projects and evidence generation. Finally, to ensure high standards of care, the collaboration will prioritize training and education for healthcare professionals within the AC Health network.
“This strategic collaboration with BD is in line with AC Health’s continued efforts to modernize and scale healthcare solutions across the country,” said Paolo Borromeo, president and CEO of AC Health. “By combining our local network and market insights with BD’s global capabilities, we aim to deliver meaningful innovation that addresses both business goals and the evolving needs of our patients and communities.”
“This MoU with AC Health underscores BD's commitment to the Philippines' national vision for a robust and equitable healthcare system. We see this collaboration as a significant step in
contributing to the nation's healthcare advancement, where our combined strengths in medical technology and healthcare delivery will drive meaningful improvements in patient outcomes, support public health priorities and build a healthier, more resilient Philippines," said Liang Lu, vice president and general manager of BD Southeast Asia.
This strategic alliance signifies a shared long-term commitment from both organizations to jointly explore and implement scalable strategies for five years, with the possibility of extension, leveraging their combined expertise and networks to achieve shared business and healthcare objectives, ultimately driving long-term value and improving health outcomes across Southeast Asia.
About AC Health
Established in 2015, Ayala Healthcare Holdings, Inc. (AC Health) is a wholly owned subsidiary of Ayala Corporation that aims to provide every Filipino accessible, affordable, and quality healthcare. Its portfolio includes Generika Drugstore, the pioneer in generic retail pharmacies; IE Medica and MedEthix, a major pharmaceutical importer and distributor; Healthway Medical Network, a network of multi-specialty clinics, ambulatory centers, and full-service hospitals; and St. Joseph Drug, a leading retail pharmacy in North and Central Luzon. Through its pillars of pharma, hospitals, and clinics, AC Health creates a seamless and integrated healthcare ecosystem for the Filipino patient.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
